Dr Lal PathLabs expands advanced diagnostics portfolio with genomics buy

•Dr Lal PathLabs acquired a 70% stake in SN Genelab for ₹168 crore.

•The deal strengthens Dr Lal's genomics expertise in India.

•SN Genelab is a leader in genomics testing in India.

•The acquisition broadens Dr Lal's advanced diagnostics portfolio.